Chris Raymond
Stock Analyst at Raymond James
(3.09)
# 1,278
Out of 5,072 analysts
9
Total ratings
77.78%
Success rate
63.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $87.36 | +40.80% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $43.79 | +2.76% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $22.03 | +58.87% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $109.15 | -3.80% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $6.44 | +257.14% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $40.39 | -25.72% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $9.48 | +691.14% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $87.36
Upside: +40.80%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $43.79
Upside: +2.76%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $22.03
Upside: +58.87%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $109.15
Upside: -3.80%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $6.44
Upside: +257.14%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $40.39
Upside: -25.72%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $9.48
Upside: +691.14%